Allegiance Financial Group Advisory Services’s Alnylam Pharmaceuticals ALNY Stock Holding History

Allegiance Financial Group Advisory Services’s Portfolio ALNY Stock Details ALNY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-462	Closed	-$211K	–	179
2025 Q3	$211K	Buy	+462	New	+$188K	0.05%	151
2025 Q2	–	Sell	-1,353	Closed	-$365K	–	156
2025 Q1	$365K	Buy	1,353 +384	+40%	+$98.7K	0.11%	74
2024 Q4	$228K	Buy	+969	New	+$255K	0.07%	88

Other funds holding ALNY

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $717B AUM 35.42% 1-Year Est. Return

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Allegiance Financial Group Advisory Services's ALNY Position: Q4 2025 in Review

Allegiance Financial Group Advisory Services sold out of Alnylam Pharmaceuticals (ALNY) in Q4 2025, closing a stake of 462 shares — an estimated $211K sold.

Allegiance Financial Group Advisory Services first reported a position in ALNY in Q4 2024 and held it in 3 quarters. The position peaked at $365K in Q1 2025. 851 funds tracked by Wall St. Rank hold ALNY as of Q4 2025.

Allegiance Financial Group Advisory Services reported no remaining Alnylam Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Allegiance Financial Group Advisory Services sold 462 Alnylam Pharmaceuticals shares in Q4 2025, an estimated $211K.
Allegiance Financial Group Advisory Services first reported a position in Alnylam Pharmaceuticals in Q4 2024 and held it in 3 quarters.
Allegiance Financial Group Advisory Services's Alnylam Pharmaceuticals position peaked at $365K in Q1 2025.
851 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q4 2025.

Based on Allegiance Financial Group Advisory Services's 13F filing for Q4 2025, filed 3 Feb 2026.